title: High leucovorin doses during high-dose methotrexate treatment may reduce the cure rate in childhood acute lymphoblastic leukemia.
abstract: We explored the relationship between time to relapse and different exposure variables (serum methotrexate (S-MTX) 23, 36 and 42 h after start of administration, MTX elimination time and leucovorin (LV) dose) during high-dose MTX (HDM) treatment of 445 children with acute lymphoblastic leukemia. MTX was infused at 5 g/m2 (non-high risk) or 8 g/m2 (high risk) over 24 h, 2-9 times per patient. LV rescue dose was adjusted according to the S-MTX concentration. Time from end of the last HDM to relapse was analyzed by Cox regression analysis with the logarithms of S-MTX and LV dose as exposures. The combined results from all risk groups suggest that high LV dose is related to higher risk for relapse. Doubling of the LV dose increased the relapse risk by 22% (95% confidence interval 1-49%, P = 0.037). High LV doses correlated with high MTX levels at 23, 36 and 42 h and longer elimination time. The results suggest that high doses of LV increase the risk for relapse despite the fact that they were correlated with high MTX levels and longer MTX elimination time. The choice of MTX and LV doses may be regarded as an intricate balance between effect and counter-effect.
authors.affiliation: Department of Pediatrics, Lund University Hospital, Lund, Sweden. tor.skarby@med.lu.se
authors.forename: T V Ch
authors.initials: TV
authors.lastname: Skärby
authors.forename: H
authors.initials: H
authors.lastname: Anderson
authors.forename: J
authors.initials: J
authors.lastname: Heldrup
authors.forename: J A
authors.initials: JA
authors.lastname: Kanerva
authors.forename: H
authors.initials: H
authors.lastname: Seidel
authors.forename: K
authors.initials: K
authors.lastname: Schmiegelow
mesh_terms: D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage*; D016022:Case-Control Studies; D002648:Child; D002675:Child, Preschool; D018572:Disease-Free Survival; D004347:Drug Interactions; D005260:Female; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage / Q000009:adverse effects*; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000453:epidemiology; D012042:Registries; D012307:Risk Factors; D055502:Secondary Prevention; D014803:Vitamin B Complex / Q000008:administration & dosage / Q000009:adverse effects*
chemical_list: D000964:Antimetabolites, Antineoplastic; D014803:Vitamin B Complex; D002955:Leucovorin; D008727:Methotrexate